Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Ipilimumab can induce durable disease control and long-term survival in patients with metastatic melanoma. Identification of a biomarker that correlates with clinical benefit and potentially provides an early marker of response is an active area of research.Patients and methods Ipilimumab was available upon physician request for patients aged ≥16 years with stage III (unresectable) or IV cutaneous, ocular or mucosal melanoma, who had failed or did not tolerate previous treatments and had no other therapeutic option available. Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. Tumour assessments were conducted at baseline, Week 12 and Week 24 using immune-related response criteria. Patients were monitored continuously for adverse events (AEs), including immune-related AEs. Candidate immunological markers were evaluated in peripheral blood and sera samples collected at baseline and Weeks 4, 7, 10 and 12.Results Among 95 patients treated with ipilimumab 3 mg/kg, the immune-related disease control rate at Week 24 was 38 %. With a median follow-up of 24 months, median overall survival was 9.6 months. Both disease control and survival were significantly associated with decreasing levels of lactate dehydrogenase, C-reactive protein and FoxP3/regulatory T cells, and increasing absolute lymphocyte count, between baseline and the end of dosing (Week 12).Conclusion Ipilimumab is a feasible treatment option for heavily pretreated patients with metastatic melanoma. Changes in some immunological markers between baseline and the fourth ipilimumab infusion appear to be associated with disease control and survival, but verification in prospective clinical trials is required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“increased lymphocyte counts in the blood are associated not only with favorable treatment outcome but also with increased overall survival in patients with melanoma treated with ICIs (132-135).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [133]
In the citing paper
“decreases in Tregs in the peripheral blood and tumors of patients with metastatic melanoma treated with ICIs have been associated with ICI response and increased patient survival”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [133]
In the citing paper
“Balatoni et al. (153) demonstrated that patients with melanoma who exhibited a higher frequency of Tregs in lymph node metastases responded better to ipilimumab compared with patients who had fewer Tregs (133).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [133]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 3×
“Ipilimumab, a monoclonal antibody against cytotoxic t-lymphocyte-associated antigen-4 (Ctla-4), was the first agent approved for the treatment of unresectable or metastatic (advanced) melanoma that showed an overall survival (OS) benefit in a randomised phase III trial [1].”
BackgroundImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationBiomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Korn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
Self-citationHamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534 · cited 3×
“taking this into consideration, it was hypothesised that tregs, and thus FoxP3, may be upregulated in the tumours of patients with ongoing, yet suboptimal, antitumour immune responses and that these individuals may be more likely to respond to ipilimumab [20].”
Background
Cited by
Items 101–200 of 253
Current and emerging systemic therapies for cutaneous metastatic melanoma
Mason, R., Au, L., Garces, A. I., & Larkin, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601700 · Cited by 46
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 44
Sun, R., Champiat, S., Dercle, L., Aspeslagh, S., Álvarez, E. C., Limkin, E. J., Baldini, C., Postel-Vinay, S. C., Hollebecque, A., Massard, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.033 · Cited by 42
Naqash, A. R., Stroud, C. R. G., Butt, M., Dy, G. K., Hegde, A. M., Muzaffar, M., Yang, L. V., Hafiz, M., Cherry, C. R., & Walker, P. R. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1415460 · Cited by 40
Hernandez, C., Arasanz, H., Chocarro, L., Bocanegra, A., Zuazo, M., Fernández-Hinojal, G., Blanco, E., Vera, R., Escors, D., & Kochan, G. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072411 · Cited by 40
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses
Kwek, S. S., Kahn, J. G., Greaney, S. K., Lewis, J., Cha, E., Zhang, L., Weber, R. W., Leonard, L., Markovic, S. N., Fong, L. H., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1101204 · Cited by 35
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.
Jazirehi, A. R., Lim, A., & Dinh, T. (2016) · PubMed Central · Cited by 37
Ouwerkerk, W., van den Berg, M., van der Niet, S., Limpens, J., & Luiten, R. M. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000589 · Cited by 44
Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers
Acebes-Fernández, V., Landeira‐Viñuela, A., Juanes‐Velasco, P., Hernández, Á., Otazo‐Pérez, A., Manzano-Román, R., Góngora, R., & Fuentes, M. (2020) · Nanomaterials · doi:10.3390/nano10071274 · Cited by 42
Specenier, P. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1211936 · Cited by 43
Karlsson, M., Svedman, F. C., Tebani, A., Kotol, D., Höiom, V., Fagerberg, L., Edfors, F., Uhlén, M., Brage, S. E., & Maddalo, G. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2000 · Cited by 40
Khunger, A., Rytlewski, J. A., Fields, P., Yusko, E. C., & Tarhini, A. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1652538 · Cited by 37
Kijima, T., Yamamoto, H., Saito, K., Kusuhara, S., Yoshida, S., Yokoyama, M., Matsuoka, Y., Numao, N., Sakai, Y., Matsubara, N., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02709-2 · Cited by 35
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Integration of Salmonella into Combination Cancer Therapy
Al-Saafeen, B. H., Fernández-Cabezudo, M. J., & al-Ramadi, B. K. (2021) · Cancers · doi:10.3390/cancers13133228 · Cited by 40
Biomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 37
Guo, C., Yang, Q., Xu, P., Deng, M., Jiang, T., Cai, L., Li, J., Sai, K., Xi, S., Ouyang, H., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.53285 · Cited by 35
Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response
Felix, J., Lambert, J., Roelens, M., Maubec, E., Guermouche, H., Pages, C., Sidina, I., Cordeiro, D. J., Maki, G., Chasset, F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1136045 · Cited by 32
“higher dose or another CTLA-4 abrogating antibody, tremelimumab.(21,22,23,38) Prior to treatment, patients’ circulating T cells”
BackgroundMaccalli, C., Giannarelli, D., Capocefalo, F., Pilla, L., Fonsatti, E., Giacomo, A. M. D., Parmiani, G., & Maio, M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1071007 · Cited by 33
Self-citationDiem, S., Fässler, M., Bomze, D., Ali, O. H., Berner, F., Niederer, R., Hillmann, D., Mangana, J., Levesque, M. P., Dummer, R., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000255 · Cited by 32
Yanagisawa, T., Mori, K., Katayama, S., Mostafaei, H., Quhal, F., Laukhtina, E., Rajwa, P., Motlagh, R. S., Aydh, A., König, F., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02061-0 · Cited by 32
Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy
Félix, J., Cassinat, B., Porcher, R., Schlageter, M., Maubec, E., Pagès, C., Baroudjian, B., Homyrda, L., Boukouaci, W., Tamouza, R., et al. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.09.030 · Cited by 35
What have we learned from cancer immunotherapy in the last 3 years?
Ascierto, P. A., & Marincola, F. M. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-141 · Cited by 33
Self-citationBiomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Balatoni, T., Ladányi, A., Fröhlich, G., Czirbesz, K., Kovacs, P. L., Pánczél, G., Bence, E., Plótár, V., & Liszkay, G. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0466-9 · Cited by 31
McFarland, D. C., Shaffer, K. M., BREITBART, W. S., Rosenfeld, B. D., & Miller, A. H. (2018) · Cancer · doi:10.1002/cncr.31859 · Cited by 32
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Zhang, M., Yang, H. J., Hua, W., Zhong, L., Xu, Z., & Qian, Q. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0678-0 · Cited by 38
The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival
Delyon, J., Maio, M., & Lebbé, C. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.005 · Cited by 35
Iivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma
LoRusso, P. M., Schalper, K. A., & Sosman, J. A. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12847 · Cited by 33
Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges
Pilla, L., & Maccalli, C. (2018) · Biomedicines · doi:10.3390/biomedicines6030076 · Cited by 30
Immunotherapy for Advanced Melanoma: Future Directions
Valpione, S., & Campana, L. G. (2016) · Immunotherapy · doi:10.2217/imt.15.111 · Cited by 31
Systematic evaluation of immune regulation and modulation
Stroncek, D. F., Butterfield, L. H., Cannarile, M. A., Dhodapkar, M. V., Greten, T. F., Grivel, J., Kaufman, D. R., Kong, H. H., Korangy, F., Lee, P. P., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0223-8 · Cited by 32
Chen, J. A., Ma, W., Yuan, J. D., & Li, T. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_9 · Cited by 31
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade
Onieva, J. L., Xiao, Q., Berciano‐Guerrero, M., Laborda-Illanes, A., de Andrea, C., Cháves, P., Piñeiro, P., Garrido-Aranda, A., Gallego, E., Sojo, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169124 · Cited by 30
Ishihara, H., Takagi, T., Kondo, T., Fukuda, H., Tachibana, H., Yoshida, K., Iizuka, J., Okumi, M., Ishida, H., & Tanabe, K. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.12.008 · Cited by 29
Baltussen, J. C., Welters, M. J. P., Verdegaal, E. M. E., Kapiteijn, E., Schrader, A. M. R., Slingerland, M., Liefers, G., van der Burg, S. H., Portielje, J. E. A., & de Glas, N. A. (2021) · Cancers · doi:10.3390/cancers13246366 · Cited by 34
Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma
Meftahpour, V., Aghebati‐Maleki, A., Fotouhi, A., Safarzadeh, E., & Maleki, L. A. (2022) · EXCLI journal · doi:10.17179/excli2021-4094 · Cited by 32
Krishnamurthy, N., Nishizaki, D., Lippman, S. M., Miyashita, H., Nesline, M., Pabla, S., Conroy, J. M., DePietro, P., Kato, S., & Kurzrock, R. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231220510 · Cited by 28
Hamuro, L., Statkevich, P., Bello, A., Roy, A., & Bajaj, G. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1502 · Cited by 27
Li, S., Zou, J., Liu, C. X., Jiao, X., Gong, J., Li, J., Wang, Z., Lu, M. S., Lü, Z., & Shen, L. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108345 · Cited by 28
Ipilimumab in a real‐world population: A prospective Phase IV trial with long‐term follow‐up
Aamdal, E., Jacobsen, K. D., Straume, O., Kersten, C., Herlofsen, O., Karlsen, J., Hussain, I., Amundsen, A., Dalhaug, A., Nyakas, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33768 · Cited by 30
Sioud, M. (2018) · Scandinavian Journal of Immunology · doi:10.1111/sji.12643 · Cited by 28
Kee, D., & McArthur, G. A. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.014 · Cited by 28
McNamara, M. J., Hilgart-Martiszus, I., Echenique, D. M. B., Linch, S. N., Kasiewicz, M. J., & Redmond, W. L. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0022 · Cited by 24
Mastracci, L., Fontana, V., Queirolo, P., Carosio, R., Grillo, F., Morabito, A., Banelli, B., Tanda, E. T., Boutros, A., Dozin, B., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02494-y · Cited by 28
Self-citationClinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists
Callahan, M. K., & Wolchok, J. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.008 · Cited by 23
Akiyama, Y., Nonomura, C., Kondou, R., Miyata, H., Ashizawa, T., Maeda, C., Mitsuya, K., Hayashi, N., Nakasu, Y., & Yamaguchi, K. D. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3586 · Cited by 23
Regulatory T cells in the immunotherapy of melanoma
Ouyang, Z., Wu, H., Li, L., Luo, Y., Li, X., & Huang, G. (2015) · Tumor Biology · doi:10.1007/s13277-015-4315-0 · Cited by 25
Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music, M., Prassas, I., & Diamandis, E. P. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1499706 · Cited by 23
Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy
Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 22
Santos-Briz, A. J., Cañueto, J., del Carmen, S., Barrios, B., Yuste‐Chaves, M., Bellido, L., de la Cruz, M. D. L., & Román, C. (2020) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001856 · Cited by 23
Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 24
D’Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., Romano, M. F., & Romano, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181106114421 · Cited by 23
Tomela, K., Pietrzak, B., SCHMIDT, M. T., & Mackiewicz, A. A. (2020) · Life · doi:10.3390/life10100219 · Cited by 26
Gearing up T-cell immunotherapy in cervical cancer
Chauhan, S. R., & Bharadwaj, M. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.04.001 · Cited by 24
Mehra, T., Dongre, K., Boesing, M., Frei, P., Suenderhauf, C., Zippelius, A., Leuppi, J. D., WICKI, A. N., & Taegtmeyer, A. B. (2023) · Cancer Medicine · doi:10.1002/cam4.5919 · Cited by 19
Immunomonitoring in glioma immunotherapy: current status and future perspectives
Lamano, J. B., Ampie, L., Choy, W., Kesavabhotla, K., DiDomenico, J. D., Oyon, D. E., Parsa, A. T., & Bloch, O. G. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2018-4 · Cited by 24
Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
Ma, K., Jin, Q., Wang, M., Li, X., & Zhang, Y. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1617702 · Cited by 21
Kubo, S., Kobayashi, N., Somekawa, K., Hirata, M., Kamimaki, C., Aiko, H., Katakura, S., Teranishi, S., Watanabe, K., Hara, Y., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14379 · Cited by 19
Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy
Strudel, M., Festino, L., Vanella, V., Beretta, M., Marincola, F. M., & Ascierto, P. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191205160007 · Cited by 18
Self-citationOvercoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
García‐Sancha, N., Corchado‐Cobos, R., Bellido-Hernández, L., Román‐Curto, C., Álvarez, E. C., Pérez‐Losada, J., Órfão, A., & Cañueto, J. (2021) · Cancers · doi:10.3390/cancers13205134 · Cited by 23
Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer
Mulvey, A., Muggeo-Bertin, E., Berthold, D., & Herrera, F. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859785 · Cited by 19
Immune checkpoint inhibitors: a milestone in the treatment of melanoma
Wilden, S. M., Lang, B. M., Mohr, P., & Grabbe, S. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13012 · Cited by 26
Checkpoint‐Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms
Wilden, S. M., Lang, B. M., Mohr, P., & Grabbe, S. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13012_g · Cited by 21
Watson, G. A., Doi, J., Hansen, A. R., & Spreafico, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14355 · Cited by 20
He, Y., Wu, Y., Liu, Z., Li, B., Jiang, N., Xu, P., & Xu, X. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.694777 · Cited by 18
Strippoli, S., Fanizzi, A., Negri, A., Quaresmini, D., Nardone, A., Armenio, A., Sciacovelli, A. M., Massafra, R., Risi, I. D., Tullio, G. D., et al. (2021) · Cells · doi:10.3390/cells10020406 · Cited by 21
Zhu, Z., Zhuang, L., Zhang, C., Ning, Z., Wang, D., Sheng, J., Hua, Y.-Q., Xie, J., Xu, L., & Meng, Z. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-1760 · Cited by 16
Romano, S., Simeone, E., D’Angelillo, A., D’Arrigo, P., Russo, M., Capasso, M., Lasorsa, V. A., Zambrano, N., Ascierto, P. A., & Romano, M. F. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2004-0 · Cited by 17
Self-citationLiu, D., Xiao, H., Xiang, Y., Zhong, D., Liu, Y., Wang, Y., & Zhang, W. (2025) · Journal of Cancer · doi:10.7150/jca.108163 · Cited by 18
van den Brom, R. R. H., van der Geest, K. S. M., Brouwer, E., Hospers, G. A. P., & Boots, A. M. H. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2148-6 · Cited by 15
Garg†, S. K., Ott, M. J., Mostofa, A., Chen, Z., Chen, Y. A., Kroeger, J. L., Cao, B., Mailloux, A. W., Agrawal, A., Schaible, B., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00164 · Cited by 13
Salinas, N., Nowak, E., Étienne, M., Legoupil, D., Fouchard, M., Brenaut, E., & Misery, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.632683 · Cited by 12
Dendritic Cell Cancer Vaccines: From the Bench to the Bedside
Katz, T., Avivi, I. M., Benyamini, N., Rosenblatt, J. M., & Avigan, D. (2014) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10158 · Cited by 12
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
Kim, H. Y., Upadhyay, P. J., Fahmy, A., Liu, X., Duong, J. K., & Boddy, A. V. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00753-5 · Cited by 14
Voutsadakis, I. A. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.03.03 · Cited by 15
Karol, A. B., Fujiwara, Y., D’Ovidio, T. J., Baldwin, E., Joshi, H. N., Doroshow, D. B., & Galsky, M. D. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2379230 · Cited by 11
Ding, H., Yuan, M., Yang, Y., Gupta, M., & Xu, S. X. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3052 · Cited by 14
Overview of Basic Immunology and Clinical Application
Stephen, B., & Hajjar, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_1 · Cited by 13
Systemic Adverse Events with Biomedicines
Tridente, G. (2014) · Cited by 15
Zhang, C., Zhang, J., Ma, Y., Zhe, H., Zhao, R., & Wang, Y. (2019) · Disease Markers · doi:10.1155/2019/1601072 · Cited by 10
Ogunleye, F. N., Blankenship, L. M., Millisor, V. E., Anderson, J., & Jaiyesimi, I. A. (2017) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2017.05.002 · Cited by 10
Ipilimumab in the treatment of advanced melanoma – a clinical update
Kim, D. W., Trinh, V. A., & Hwu, W. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.963053 · Cited by 11
Immunogenomics: using genomics to personalize cancer immunotherapy
Siniard, R. C., & Harada, S. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2140-0 · Cited by 10
Ürün, Y., Yaşar, A., Turna, H., Esin, E., Sedef, A. M., Alkan, A., Öksüzoğlu, B. Ç., Özdemir, N., Sendur, M. N., Sezer, A., et al. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218805539 · Cited by 10
Min, K., Choe, J., Kwon, M. J., Lee, H., Kang, H. S., Nam, E. S., Cho, S. J., Park, H., Min, S. K., Seo, J., et al. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152671 · Cited by 9
McCallen, J., Naqash, A. R., Marie, M. A., Atwell, D. C., Muzaffar, M., Sharma, N. J., Amara, S., Liles, D., Walker, P. R., & Yang, L. V. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1917001 · Cited by 10
Kurzhals, J. K., Klee, G., Hagelstein, V., Zillikens, D., Terheyden, P. A. M., & Langan, E. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810723 · Cited by 9
Chen, W., Li, D., Bian, X., Wu, Y. T., Xu, M., Wu, M., & Tao, M. (2022) · Nutrition and Cancer · doi:10.1080/01635581.2022.2123533 · Cited by 9
Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices
Pagès, F., Granier, C., Kirilovsky, A., Sissy, C. E., & Tartour, É. (2016) · Bulletin du Cancer · doi:10.1016/s0007-4551(16)30373-3 · Cited by 8
Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer
Raza, A., Merhi, M., Relecom, A., Fernandes, Q., Inchakalody, V. P., Gul, A. R. Z., Shahab Uddin, M. S., Homsi, M. U. A., & Dermime, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96494 · Cited by 10
Cancer immunotherapy: A need for peripheral immunodynamic monitoring
Wang, W., Xia, X., Wu, S.-P., Guo, M., Lie, P., & He, J. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12793 · Cited by 8
Melanoma: the role of surgery in the era of new therapies
Mozzillo, N., & Ascierto, P. A. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-195 · Cited by 7
Self-citationLoo, K. L., Gauvin, G., Soliman, I., Renzetti, M., Deng, M., Ross, E. A., Luo, B., Wu, H. G., Reddy, S. S., Olszanski, A. J., et al. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12909 · Cited by 8
Overview of Basic Immunology and Translational Relevance for Clinical Investigators
Stephen, B., & Hajjar, J. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_1 · Cited by 8
Luminal A breast cancer resistance mechanisms and emerging treatments
Anderson, D. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00010-3 · Cited by 16
Ji, C., Kumpf, S. W., Qian, J., Federspiel, J. D., Sheehan, M. J., Capunitan, D. C., Atallah, E., Astbury, S., Arat, S., Oziolor, E. M., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04033-z · Cited by 10
Melanoma: 18F-FDG PET/CT for Response Assessment of Melanoma Following Immunotherapy
Sachpekidis, C., & Dimitrakopoulou‐Strauss, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-31113-1_6 · Cited by 8
Schumacher, M., Beer, S. A., Ribeiro, E. M., Korkmaz, F., Keppeler, H., Fitzel, R., Erkner, E., Radszuweit, P., Lengerke, C., Schneidawind, C., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1333640 · Cited by 7
Omar, N. E., Elazzazy, S., Hamad, A. A., Saad, M. O., Alasmar, A., Nasser, S. M., Benkhadra, M., Afifi, H. M., Jibril, F. I., Dawoud, R. A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1665716 · Cited by 6
Metadata
- Authors
- Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., Sandomenico, F., Petrillo, A., Botti, G., Fulciniti, F., Palmieri, G., Queirolo, P., Marchetti, P., Ferraresi, V., Rinaldi, G., Pistillo, M. P., Ciliberto, G., Mozzillo, N., & Ascierto, P. A.
- Affiliations
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Instituto Nazionale Tumori Regina Elena (IT)
- National Research Council (IT)
- Ospedale Policlinico San Martino (IT)
- Istituto Dermopatico dell'Immacolata (IT)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Corresponding author
- Ascierto, Paolo A.
- ORCID
- Simeone, Ester
- Gentilcore, Giusy
- Giannarelli, Diana
- Grimaldi, Antonio M.
- Caracò, Corrado
- Curvietto, Marcello
- Esposito, Assunta
- Paone, Miriam
- Palla, Marco
- Cavalcanti, Ernesta
- Sandomenico, Fabio
- Petrillo, Antonella
- Botti, Gerardo
- Fulciniti, Franco
- Palmieri, Giuseppe
- Queirolo, Paola
- Marchetti, Paolo
- Ferraresi, Virginia
- Pistillo, Maria Pia
- Ciliberto, Gennaro
- Ascierto, Paolo A.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2014-04-03
- Volume
- 63
- Issue
- 7
- Pages
- 675-683
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11028686
- OpenAlex
- W1965215390
- Cited by
- 253
- References
- 32
- Citations by year
- 2025: 8 · 2024: 4 · 2023: 11 · 2022: 15 · 2021: 27 · 2020: 38 · 2019: 38 · 2018: 27 · 2017: 25 · 2016: 29 · 2015: 21 · 2014: 8
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-09-25)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, metastatic melanoma, immune checkpoint inhibitors, predictive biomarkers, immune-related adverse events, regulatory T cells, Foxp3, lactate dehydrogenase, C-reactive protein, lymphocyte count, disease control rate, overall survival, immune-related response criteria
- MeSH terms
- Ipilimumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Eye Neoplasms, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Analysis, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.